<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760522</url>
  </required_header>
  <id_info>
    <org_study_id>GE-MED APPROACH</org_study_id>
    <nct_id>NCT04760522</nct_id>
  </id_info>
  <brief_title>Genome-based Management of Patients in Precision Medicine (Ge-Med) Towards a Genomic Health Program</brief_title>
  <acronym>GE-MED</acronym>
  <official_title>Genome-based Management of Patients in Precision Medicine (Ge-Med) Towards a Genomic Health Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GE-MED APPROACH project will enroll patients (n = appr. 12.000) with unclear molecular&#xD;
      cause of the disease, suspected genetic cause of the disease without detailed molecular&#xD;
      analysis like Whole Exome Sequencing (WES).&#xD;
&#xD;
      The novelty of this study is to integrate genomic health concepts into immediate clinical&#xD;
      care. To achieve these goals, a novel structure for the Triple P (3P) concept of personalized&#xD;
      medicine (Personalized, Predictive, Preventive) integrated into a well-established health&#xD;
      care system and associated with novel decentralized Disease Analysing Task Forces (DATF) will&#xD;
      be implemented.&#xD;
&#xD;
      The overall goal of this study is to implement, for the first time, Whole Genome Sequencing&#xD;
      (WGS) analysis as a first line diagnostic test for all clinical indications such as Rare&#xD;
      Disease (RD )and familial cancer syndromes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">July 2027</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of WGS analysis</measure>
    <time_frame>Day 1</time_frame>
    <description>WGS analysis as a first line diagnostic test for all clinical indications</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>Rare Diseases</condition>
  <condition>Genetic Predisposition to Disease</condition>
  <arm_group>
    <arm_group_label>WGS Diagnostic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Both underage and adult persons (male and female) with diagnostically unsolved rare diseases who have been or are included into diagnostic care at the University Hospital Tübingen, Germany (UKT) and who are suspected of having a genetic cause of the disease.&#xD;
Study related procedures: Blood sampling, anamnesis including pedigree, Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics).</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>WGS Diagnostic: Blood take for genetic diagnostic</intervention_name>
    <description>Blood sampling, short clinical characterization, WGS based sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics).</description>
    <arm_group_label>WGS Diagnostic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unclear molecular cause of the disease&#xD;
&#xD;
          -  Suspected genetic cause of the disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Missing informed consent of the patient and if applicable the legal representative&#xD;
&#xD;
          -  Previously performed WES or panel analysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olaf Rieß, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Tübingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olaf Rieß, Prof. Dr.</last_name>
    <phone>+49 7071 29</phone>
    <phone_ext>72323</phone_ext>
    <email>olaf.riess@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Dufke, PD Dr.</last_name>
    <phone>+49 7071 29</phone>
    <phone_ext>72190</phone_ext>
    <email>andreas.dufke@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olaf Rieß, Prof. Dr.</last_name>
      <phone>+49 7071 29</phone>
      <phone_ext>72323</phone_ext>
      <email>olaf.riess@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Dufke, PD Dr.</last_name>
      <phone>+49 7071 29</phone>
      <email>andreas.dufke@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rare Diseases</keyword>
  <keyword>Genetic Predisposition</keyword>
  <keyword>Whole Exome Sequencing (WES)</keyword>
  <keyword>Whole Genome Sequencing (WGS)</keyword>
  <keyword>Familial cancer syndromes</keyword>
  <keyword>Polygenic Risk Scores (PRS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rare Diseases</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The GE-MED APPROACH study will provide data in a pseudonymized manner to national and international databases set up to increase the diagnostic yield through advanced analysis tools and matchmaking against other cohorts</ipd_description>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will become available after analysis and unlimited.</ipd_time_frame>
    <ipd_access_criteria>Authorized users within the participating organizations.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

